VAPILIR atorvastatin (as calcium) 20 mg film-coated tablet blister pack

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

atorvastatin calcium, Quantity: 20.68 mg (Equivalent: atorvastatin, Qty 20 mg)

Disponible depuis:

Medis Pharma Pty Ltd

DCI (Dénomination commune internationale):

Atorvastatin calcium

forme pharmaceutique:

Tablet, film coated

Composition:

Excipient Ingredients: colloidal anhydrous silica; microcrystalline cellulose; hyprolose; pregelatinised maize starch; magnesium stearate; activated attapulgite; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000

Mode d'administration:

Oral

Unités en paquet:

50, 40, 30, 10, 20

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

As an adjunct to diet for the treatment of patients with hypercholesterolaemia. Prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,Indicated in hypertensive patients with multiple risk factors for coronary heart disease (CHD), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic CHD (see CLINICAL TRIALS, Prevention of Cardiovascular Disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Descriptif du produit:

Visual Identification: White, oval bi-convex tablets with breakline on one side; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Statut de autorisation:

Licence status A

Date de l'autorisation:

2011-09-16